Jefferies Financial Group Inc. Purchases 49,461 Shares of Maximus, Inc. $MMS

Posted by Francis Steltz on May 26th, 2026

Jefferies Financial Group Inc. raised its stake in shares of Maximus, Inc. (NYSE:MMS – Free Report) by 453.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,361 shares of the health services provider’s stock after purchasing an additional 49,461 shares during the quarter. Jefferies Financial Group Inc. owned about 0.11% of Maximus worth $5,210,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Boston Partners boosted its holdings in shares of Maximus by 47.0% in the 3rd quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after acquiring an additional 308,892 shares during the last quarter. UBS Group AG boosted its holdings in shares of Maximus by 76.8% in the 4th quarter. UBS Group AG now owns 610,354 shares of the health services provider’s stock valued at $52,686,000 after acquiring an additional 265,095 shares during the last quarter. Qube Research & Technologies Ltd boosted its holdings in shares of Maximus by 115.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 379,342 shares of the health services provider’s stock valued at $26,630,000 after acquiring an additional 203,521 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Maximus in the 4th quarter valued at $15,673,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Maximus in the 3rd quarter valued at $15,397,000. Institutional investors and hedge funds own 97.21% of the company’s stock.

Insider Buying and Selling

In other Maximus news, Director Jan Madsen sold 742 shares of Maximus stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $72.25, for a total transaction of $53,609.50. Following the transaction, the director directly owned 20,795 shares of the company’s stock, valued at $1,502,438.75. The trade was a 3.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.80% of the stock is owned by company insiders.

Maximus Stock Down 0.1%

MMS stock opened at $61.09 on Tuesday. The stock has a market capitalization of $3.21 billion, a P/E ratio of 9.15 and a beta of 0.60. The firm has a 50-day simple moving average of $65.26 and a 200-day simple moving average of $77.89. The company has a quick ratio of 2.21, a current ratio of 2.21 and a debt-to-equity ratio of 0.87. Maximus, Inc. has a 52 week low of $56.92 and a 52 week high of $100.00.

Maximus (NYSE:MMS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The health services provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.32 billion. Maximus had a net margin of 7.02% and a return on equity of 25.10%. Maximus’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 EPS. Maximus has set its FY 2026 guidance at 8.250-8.550 EPS. Equities analysts forecast that Maximus, Inc. will post 8.4 earnings per share for the current fiscal year.

Maximus Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a dividend of $0.33 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.32 dividend on an annualized basis and a yield of 2.2%. Maximus’s payout ratio is 19.76%.

Analyst Upgrades and Downgrades

MMS has been the topic of several recent research reports. Zacks Research downgraded shares of Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Wall Street Zen downgraded shares of Maximus from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Finally, Weiss Ratings downgraded shares of Maximus from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 20th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold”.

Read Our Latest Report on MMS

Maximus Profile

(Free Report)

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.